Literature DB >> 9842429

Differences in blood-tumour-barrier leakage of human intracranial tumours: quantitative monitoring of vasogenic oedema and its response to glucocorticoid treatment.

C Andersen1, F T Jensen.   

Abstract

PURPOSE: To study differences in tumour capillary permeability as expressed by the unidirectional transport rate constant Ki, extracellular distribution volume Vd and relaxation time T1 in human intracranial tumours using a recently described MRI method, and apply the model to study differences in these parameters after glucocorticoid (GC) treatment. PATIENTS AND METHODS: Seventeen brain tumour patients were studied. There were seven glioblastoma (GLI), four metastasis (MET), and six meningioma (MM) patients. Nine patients were studied before and after an average of 6 days of GC treatment. A 1.5 Tesla MR imaging scanner was used, and a two compartment diffusion model for Gd-DTPA was applied.
RESULTS: There was a significant difference between pre-treatment Ki in GLI's and MM's, MM's having the highest permeability. There were no significant differences between pre-treatment Vd or T1 among the different tumour types. After GC treatment Ki decreased 15% on average (52% in GLI's and MET's, but only 4% in MM's). Vd decreased 14% on average in all tumours, but 47% in GLI's and MET's (p < 0.04), but increased 2% during treatment of MM's. T1 decreased 9% in all tumours (p < 0.04), but 11% in GLI's and MET's (p < 0.003), and only 6% in MM's.
CONCLUSIONS: It is possible to estimate Ki, Vd and T1 simultaneously in brain tumour patients in a clinical MRI system. Ki was significantly higher in MM's compared to GLI's and MET's suggesting that MM's differ in some physiological parameter at the blood-tumour interface. MM's did not respond to GC treatment, neither in Ki, Vd nor in T1, whereas GLI's and MET's primarily decreased their extracellular distribution volume, suggesting that this may be an important effect in GC's mode of action in these tumour types.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9842429     DOI: 10.1007/s007010050194

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  10 in total

1.  Candidate biomarkers of extravascular extracellular space: a direct comparison of apparent diffusion coefficient and dynamic contrast-enhanced MR imaging--derived measurement of the volume of the extravascular extracellular space in glioblastoma multiforme.

Authors:  S J Mills; C Soh; C J Rose; S Cheung; S Zhao; G J M Parker; A Jackson
Journal:  AJNR Am J Neuroradiol       Date:  2009-10-22       Impact factor: 3.825

2.  Dynamic susceptibility-weighted perfusion imaging of high-grade gliomas: characterization of spatial heterogeneity.

Authors:  Janine M Lupo; Soonmee Cha; Susan M Chang; Sarah J Nelson
Journal:  AJNR Am J Neuroradiol       Date:  2005 Jun-Jul       Impact factor: 3.825

3.  Walker 256 tumour cells increase substance P immunoreactivity locally and modify the properties of the blood-brain barrier during extravasation and brain invasion.

Authors:  Kate M Lewis; Elizabeth Harford-Wright; Robert Vink; Alan J Nimmo; Mounir N Ghabriel
Journal:  Clin Exp Metastasis       Date:  2012-05-19       Impact factor: 5.150

4.  Inhibition of SUR1 decreases the vascular permeability of cerebral metastases.

Authors:  Eric M Thompson; Gregory L Pishko; Leslie L Muldoon; Edward A Neuwelt
Journal:  Neoplasia       Date:  2013-05       Impact factor: 5.715

5.  Evaluation of human brain tumor heterogeneity using multiple T1-based MRI signal weighting approaches.

Authors:  Manus J Donahue; Jaishri O Blakeley; Jinyuan Zhou; Martin G Pomper; John Laterra; Peter C M van Zijl
Journal:  Magn Reson Med       Date:  2008-02       Impact factor: 4.668

6.  Use of dynamic contrast-enhanced MRI to measure subtle blood-brain barrier abnormalities.

Authors:  Paul A Armitage; Andrew J Farrall; Trevor K Carpenter; Fergus N Doubal; Joanna M Wardlaw
Journal:  Magn Reson Imaging       Date:  2010-10-27       Impact factor: 2.546

Review 7.  Pathophysiology of chronic subdural haematoma: inflammation, angiogenesis and implications for pharmacotherapy.

Authors:  Ellie Edlmann; Susan Giorgi-Coll; Peter C Whitfield; Keri L H Carpenter; Peter J Hutchinson
Journal:  J Neuroinflammation       Date:  2017-05-30       Impact factor: 8.322

8.  Dex-CSDH randomised, placebo-controlled trial of dexamethasone for chronic subdural haematoma: report of the internal pilot phase.

Authors:  Ellie Edlmann; Eric P Thelin; Karen Caldwell; Carole Turner; Peter Whitfield; Diederik Bulters; Patrick Holton; Nigel Suttner; Kevin Owusu-Agyemang; Yahia Z Al-Tamimi; Daniel Gatt; Simon Thomson; Ian A Anderson; Oliver Richards; Monica Gherle; Emma Toman; Dipankar Nandi; Phillip Kane; Beatrice Pantaleo; Carol Davis-Wilkie; Silvia Tarantino; Garry Barton; Hani J Marcus; Aswin Chari; Antonio Belli; Simon Bond; Rafael Gafoor; Sarah Dawson; Lynne Whitehead; Paul Brennan; Ian Wilkinson; Angelos G Kolias; Peter J A Hutchinson
Journal:  Sci Rep       Date:  2019-04-10       Impact factor: 4.379

9.  Mitotic Activity in Glioblastoma Correlates with Estimated Extravascular Extracellular Space Derived from Dynamic Contrast-Enhanced MR Imaging.

Authors:  S J Mills; D du Plessis; P Pal; G Thompson; G Buonacorrsi; C Soh; G J M Parker; A Jackson
Journal:  AJNR Am J Neuroradiol       Date:  2015-12-24       Impact factor: 3.825

10.  "Comet tail sign": A pitfall of post-gadolinium magnetic resonance imaging findings for metastatic brain tumors.

Authors:  Koichi Mitsuya; Yoko Nakasu; Yoshitaka Narita; Satoshi Nakasu; Makoto Ohno; Yasuji Miyakita; Masato Abe; Ichiro Ito; Nakamasa Hayashi; Masahiro Endo
Journal:  J Neurooncol       Date:  2016-02-02       Impact factor: 4.130

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.